Breast Cancer and Anesthesia

2019 ◽  
Vol 25 (28) ◽  
pp. 2998-3004 ◽  
Author(s):  
Aida Raigon-Ponferrada ◽  
María E.D. Recio ◽  
Jose L. Guerrero-Orriach ◽  
Alfredo Malo-Manso ◽  
Juan J. Escalona-Belmonte ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multidisciplinary Approach ◽  
Biological Therapy ◽  
Comprehensive Treatment ◽  
Medical Oncologists

: Breast cancer is a complex heterogeneous disease that is categorized into several histological and genomic subtypes with relevant prognostic and therapeutical implications. Such diversity requires a multidisciplinary approach for a comprehensive treatment that will involve surgeons, radiotherapists and medical oncologists. Breast cancer is classified as either local (or locoregional), which stands for 90-95% of cases, or metastatic, representing 5% of cases. : The management of breast cancer will be determined by the stage of the disease. The treatment of local breast cancer is based on surgery and/or radiotherapy. Systemic breast cancer requires chemotherapy and/or endocrine and/or biological therapy.

scholarly journals The Importance of Multidisciplinary Cardio-Oncology Team in the Breast Cancer Treatment with Anthracyclines

2021 ◽  
Vol 18 (4) ◽  
pp. 67-75
Author(s):  
Diana-Lavinia Pricope ◽  
Florin Mitu
Keyword(s):  
Breast Cancer ◽  
Cardiovascular Disease ◽  
Cancer Treatment ◽  
Multidisciplinary Approach ◽  
Biological Therapy ◽  
Breast Cancer Treatment ◽  
Therapeutic Decision ◽  
Antitumoral Effect ◽  
Her2 Breast Cancer ◽  
Oncologic Treatment

Abstract The anthracyclines, represented by Doxorubicin, Epirubicin or Idarubicin, are paramount in Oncology due to their antitumoral efficacy in a multitude of solid cancers, making them essential in breast cancer treatment. The biggest disadvantage of anthracyclines, cardiotoxicity, happens as a direct effect of the oncologic treatment on the anatomy and the physiology of the heart and acts also as an element which advances pre-existent cardiovascular disease(2). We are presenting the case of a 51-year-old lady, clinically, with imagistic and biopsy diagnosis of breast cancer cT3N3M0, negative HR, HER 2neu-3+, that was treated with neoadjuvant chemotherapy consisting of anthracyclines and biological therapy with Herceptin (Trastuzumab – monoclonal humanized IgG1 antibodies, administered in HER2 + breast cancer). By cumulating the current clinical data with the therapeutic challenges of the anthracyclines (antitumoral effect vs cardiotoxicity), we are trying to encourage the multidisciplinary approach (oncology and cardiology), in order to reach the best therapeutic decision for each patient.

Oncology

2016 ◽  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Basic Science ◽  
Multidisciplinary Approach ◽  
Biological Therapy ◽  
Symptom Control ◽  
Diagnostic Techniques ◽  
Paraneoplastic Syndromes ◽  
Basic Training ◽  
Screening Strategies

Chapter 15 covers the basic science and clinical topics relating to oncology which trainees are required to learn as part of their basic training and demonstrate in the MRCP. It covers basic science, genetics in oncology, screening strategies in oncology, diagnostic techniques in oncology, oncological emergencies, breast cancer and lymphoma, prostate cancer, paraneoplastic syndromes, chemotherapy, biological therapy, and targeted therapy, radiotherapy, end of life: the multidisciplinary approach, and symptom control.

scholarly journals Linguistic Markers of Processing Trauma Experience in Women’s Written Narratives During Different Breast Cancer Phases: Implications for Clinical Interventions

2015 ◽  
Vol 11 (4) ◽  
pp. 651-663 ◽  
Author(s):  
Maria Luisa Martino ◽  
Raffaella Onorato ◽  
Maria Francesca Freda
Keyword(s):  
Breast Cancer ◽  
Cognitive Processes ◽  
Expressive Writing ◽  
Repeated Measures ◽  
Emotional Processing ◽  
Biological Therapy ◽  
Therapy Group ◽  
Negative Emotions ◽  
Entire Group ◽  
Linguistic Markers

Research into the change processes underlying the benefits of expressive writing is still incomplete. To fill this gap, we investigated the linguistic markers of change in cognitive and emotional processing among women with breast cancer, highlighting the differences and peculiarities during different treatment phases. A total of 60 writings were collected from 20 women: 10 receiving chemotherapy and 10 receiving biological therapy. We performed a series of repeated measures ANOVA for the most meaningful LIWC linguistic categories, including positive/negative emotions and cognitive processes, to assess change over three sessions. Results demonstrated a significant increase in the positive emotions category for the entire group of women, with particular relevance for the biological therapy group of women, and a marginally significant (p = .07) greater use of words indicating cognitive processes for women receiving biological therapy. For the negative emotions category time was significant for the whole group of women, showing a peak of use in the second session of writing. Peculiar differences in the linguistic markers of processing trauma were observed between the two groups. Although the writing intervention is a support for both groups of women, it seems to be beneficial when there is a large time gap since the administration of chemotherapy and, thus, when the patient can revisit the experience. The relationship of the illness with life can be rearticulated, and the writing becomes a space for resignifying the traumatic cancer experience.

scholarly journals The role of the neoadjuvant approach in the treatment of primary operable HER2 positive breast cancer

2020 ◽  
Vol 10 (2) ◽  
pp. 45-52
Author(s):  
M. A. Frolova ◽  
Е. V. Glazkova ◽  
A. V. Petrovsky ◽  
О. V. Krokhina ◽  
M. В. Stenina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Response ◽  
Residual Tumor ◽  
Response To Treatment ◽  
Comprehensive Treatment ◽  
Her2 Positive ◽  
Ki 67 ◽  
Her2 Positive Breast Cancer ◽  
Neoadjuvant Systemic Therapy ◽  
Positive Breast Cancer

Neoadjuvant systemic therapy is an essential component of the comprehensive treatment of primary operable HER2‑positive breast cancer. Therefore, it is extremely important to search for treatment efficacy predictors and optimal system for assessing tumor response to treatment. The study analyzed factors predicting pathological complete response (pCR) in patients with luminal and non‑luminal HER2‑positive tumor subtypes. The morphological assessment of the tumor response to treatment was carried out using the RCB system; additional characteristics of the residual tumor were studied as well. It was shown that a comprehensive assessment involving the use of the RCB system and determination of the Ki ‑ 67 level helps to divide patients into prognostic groups and individualize the adjuvant therapy plan.

scholarly journals Towards an optimal multidisciplinary approach to breast cancer treatment for older women

2015 ◽  
Vol 25 (4) ◽  
pp. 384-395 ◽  
Author(s):  
Nemica Thavarajah ◽  
Ines Menjak ◽  
Maureen Trudeau ◽  
Rajin Mehta ◽  
Frances Wright ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Older Women ◽  
Multidisciplinary Approach ◽  
Breast Cancer Treatment

scholarly journals Comprehensive treatment of early breast cancer

Onkologie ◽  
2020 ◽  
Vol 14 (4) ◽  
pp. 148-156
Author(s):  
Vlastimila Čmejlová
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Comprehensive Treatment

scholarly journals Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment

2020 ◽  
Vol 16 (33) ◽  
pp. 2713-2722
Author(s):  
Bruce Feinberg ◽  
Skyler Hime ◽  
Jeff Wojtynek ◽  
Igoni Dokubo ◽  
Ajeet Gajra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Discrete Choice Experiment ◽  
Discrete Choice ◽  
Triple Negative Breast Cancer ◽  
Choice Experiment ◽  
Triple Negative ◽  
Menopausal Status ◽  
Medical Oncologists ◽  
Clinical Scenarios

Aim: Guidelines list atezolizumab with nab-paclitaxel (ANP) as the preferred first-line (1L) therapy for metastatic triple-negative breast cancer (mTNBC) with PD-L1 expression ≥1%, but which clinical attributes impact ANP prescribing? Materials & methods: Medical oncologists participated in a discrete choice experiment (DCE) with four hypothetical mTNBC clinical scenarios to assess influences of: PD-L1 expression, menopausal status, prior adjuvant therapy and bulky liver metastases. Results: A total of 47% chose ANP in 1L irrespective of menopausal status, prior adjuvant therapy or tumor bulk. PD-L1 expression was the only attribute with a significant impact on ANP preference, with 69% choosing ANP for those with ≥1% expression versus only 26% for those with <1% (p < 0.00001). Conclusion: ANP choice for 1L mTNBC deviated from guidelines.

Sign in / Sign up

Export Citation Format

Share Document